JP2021507712A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021507712A5 JP2021507712A5 JP2020534609A JP2020534609A JP2021507712A5 JP 2021507712 A5 JP2021507712 A5 JP 2021507712A5 JP 2020534609 A JP2020534609 A JP 2020534609A JP 2020534609 A JP2020534609 A JP 2020534609A JP 2021507712 A5 JP2021507712 A5 JP 2021507712A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- fragments
- fragment
- amino acids
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023126388A JP7698678B2 (ja) | 2017-12-20 | 2023-08-02 | エプスタインバールウイルス抗原構築物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762608038P | 2017-12-20 | 2017-12-20 | |
| US62/608,038 | 2017-12-20 | ||
| PCT/IB2018/060101 WO2019123169A1 (en) | 2017-12-20 | 2018-12-14 | Epstein-barr virus antigen constructs |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023126388A Division JP7698678B2 (ja) | 2017-12-20 | 2023-08-02 | エプスタインバールウイルス抗原構築物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021507712A JP2021507712A (ja) | 2021-02-25 |
| JP2021507712A5 true JP2021507712A5 (enExample) | 2022-01-06 |
Family
ID=65363319
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020534609A Pending JP2021507712A (ja) | 2017-12-20 | 2018-12-14 | エプスタインバールウイルス抗原構築物 |
| JP2023126388A Active JP7698678B2 (ja) | 2017-12-20 | 2023-08-02 | エプスタインバールウイルス抗原構築物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023126388A Active JP7698678B2 (ja) | 2017-12-20 | 2023-08-02 | エプスタインバールウイルス抗原構築物 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11773139B2 (enExample) |
| EP (1) | EP3728291A1 (enExample) |
| JP (2) | JP2021507712A (enExample) |
| KR (1) | KR20200101394A (enExample) |
| CN (2) | CN118308379A (enExample) |
| AU (1) | AU2018392884B2 (enExample) |
| BR (1) | BR112020012361A2 (enExample) |
| CA (1) | CA3085975A1 (enExample) |
| EA (1) | EA202091178A1 (enExample) |
| IL (1) | IL275296A (enExample) |
| MX (1) | MX2020006225A (enExample) |
| SG (1) | SG11202005451SA (enExample) |
| WO (1) | WO2019123169A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111394376B (zh) * | 2020-03-30 | 2023-04-28 | 济宁医学院 | 一种融合基因bfna、重组腺病毒及其制备方法和应用 |
| US20240366754A1 (en) * | 2021-10-15 | 2024-11-07 | BioNTech SE | Pharmaceutical compositions for delivery of viral antigens and related methods |
| CA3260357A1 (en) * | 2022-06-29 | 2024-01-04 | Bavarian Nordic A/S | RECOMBINANT MODIFIED ANKARA VIRUS (MVA) AND SMALL ACTIVATOR RNA (SPR) PRIMARY IMMUNIZATION REGIMEN |
| WO2024084091A1 (en) | 2022-10-21 | 2024-04-25 | Medizinische Universität Wien | Materials and methods to treat epstein-barr virus (ebv) and ebv-induced diseases |
| WO2025144717A1 (en) * | 2023-12-27 | 2025-07-03 | Replicate Bioscience, Inc. | Compositions and methods for inducing immune response against epstein-barr viruses |
| WO2025229572A1 (en) * | 2024-05-01 | 2025-11-06 | Glaxosmithkline Biologicals Sa | Epstein-barr virus antigen-encoding messenger ribonucleic acid and antigen protein vaccines |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5716845A (en) * | 1995-07-20 | 1998-02-10 | Wisconsin Alumni Research Foundation | Immortalized lymphocytes for production of viral-free proteins |
| CA2154854C (en) * | 1994-07-30 | 2006-03-14 | William M. Sugden | Immortalized lymphocytes for production of viral-free proteins |
| DE4427117C1 (de) * | 1994-07-30 | 1995-10-19 | Gsf Forschungszentrum Umwelt | Plasmid und damit transfizierte Zellen |
| AU4255397A (en) | 1996-09-06 | 1998-03-26 | Trustees Of The University Of Pennsylvania, The | Chimpanzee adenovirus vectors |
| AU756081B2 (en) * | 1997-07-10 | 2003-01-02 | Council Of The Queensland Institute Of Medical Research, The | CTL epitopes from EBV |
| WO2002042480A2 (en) | 2000-11-23 | 2002-05-30 | Bavarian Nordic A/S | Modified vaccinia ankara virus variant |
| US7445924B2 (en) | 2000-11-23 | 2008-11-04 | Bavarian Nordic A/S | Modified Vaccinia Ankara virus variant and cultivation method |
| HU228327B1 (en) | 2001-06-22 | 2013-03-28 | Wistar Inst | Methods of inducing a cytotoxic immune response and recombinant simian adenovirus compositions useful therein |
| DK1711518T3 (da) | 2004-01-23 | 2010-04-06 | Angeletti P Ist Richerche Bio | Vaccinebærere for chimpanse-adenovirus |
| JP4896021B2 (ja) | 2004-05-21 | 2012-03-14 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド | 呼吸器系病原体ワクチンのためのアルファウイルスベクター |
| FR2881746B1 (fr) * | 2005-02-07 | 2007-04-13 | Centre Nat Rech Scient | Epitopes t cd4+des antigenes de latence de type i et ii du virus epstein-barr aptes a etre reconnus par la majorite des individus de la population caucasienne et leurs applications |
| JP4824389B2 (ja) * | 2005-10-28 | 2011-11-30 | 株式会社医学生物学研究所 | エプスタイン−バールウイルス感染細胞を特異的に攻撃する細胞傷害性ｔ細胞エピトープペプチド及びその用途 |
| AU2006338570B2 (en) | 2005-11-18 | 2013-07-11 | The Ohio State University Research Foundation | Viral gene products and methods for vaccination to prevent viral associated diseases |
| KR20080098585A (ko) * | 2005-12-06 | 2008-11-11 | 새빈 테라퓨틱스 피티와이 엘티디 | 엡스타인-바르 바이러스 관련 질환의 치료 |
| US20090324630A1 (en) * | 2008-04-21 | 2009-12-31 | Jensen Michael C | Fusion multiviral chimeric antigen |
| AU2010209938A1 (en) | 2009-02-02 | 2011-08-25 | Glaxosmithkline Biologicals Sa | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
| WO2011005799A2 (en) | 2009-07-06 | 2011-01-13 | Novartis Ag | Self replicating rna molecules and uses thereof |
| DK2590676T3 (en) | 2010-07-06 | 2016-10-24 | Glaxosmithkline Biologicals Sa | Virionlignende feed particles to self-replicating RNA molecules |
| HUE047796T2 (hu) | 2010-07-06 | 2020-05-28 | Glaxosmithkline Biologicals Sa | RNS bevitele több immunútvonal bekapcsolására |
| AU2011316164B2 (en) | 2010-10-15 | 2016-01-14 | Bavarian Nordic A/S | Recombinant modified vaccinia virus Ankara (MVA) influenza vaccine |
| WO2012089231A1 (en) | 2010-12-30 | 2012-07-05 | Okairòs Ag | Paramyxovirus vaccines |
| JP6091435B2 (ja) | 2011-02-22 | 2017-03-08 | カリフォルニア インスティチュート オブ テクノロジー | アデノ随伴ウイルス（ａａｖ）ベクターを用いたタンパク質の送達 |
| US9402916B2 (en) * | 2011-03-17 | 2016-08-02 | The University Of Birmingham | Re-directed immunotherapy |
| EP3854413A1 (en) | 2011-07-06 | 2021-07-28 | GlaxoSmithKline Biologicals SA | Immunogenic combination compositions and uses thereof |
| EP3508219A1 (en) | 2011-07-06 | 2019-07-10 | GlaxoSmithKline Biologicals S.A. | Self-replicating rna prime - protein boost vaccines |
| BR112015002131B1 (pt) | 2012-08-01 | 2022-11-01 | Bavarian Nordic A/S | Vírus vaccinia ankara modificado (mva) recombinante, composição farmacêutica e uso do referido mva recombinante |
| WO2014059489A1 (en) * | 2012-10-19 | 2014-04-24 | The Council Of The Queensland Institute Of Medical Research | Improved human herpesvirus immunotherapy |
| GB201312133D0 (en) * | 2013-07-05 | 2013-08-21 | Univ Birmingham | Immunotherapy |
| CN105792842B (zh) * | 2013-10-11 | 2020-06-02 | 美利坚合众国, 由健康及人类服务部部长代表 | 埃巴病毒疫苗 |
| CA2951430A1 (en) | 2014-06-13 | 2015-12-17 | Glaxosmithkline Biologicals Sa | Immunogenic combinations |
| WO2016149384A1 (en) * | 2015-03-18 | 2016-09-22 | University Of Massachusetts | Virus-like particle compositions and vaccines against epstein-barr virus infection and disease |
| JP6983665B2 (ja) | 2015-06-12 | 2021-12-17 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | アデノウイルスポリヌクレオチド及びポリペプチド |
| WO2019055887A1 (en) * | 2017-09-16 | 2019-03-21 | City Of Hope | PSEUDO-VIRAL PARTICLES OF MULTIVALENT EPSTEIN-BARR VIRUS AND USES THEREOF |
-
2018
- 2018-12-14 CA CA3085975A patent/CA3085975A1/en active Pending
- 2018-12-14 BR BR112020012361-7A patent/BR112020012361A2/pt not_active IP Right Cessation
- 2018-12-14 SG SG11202005451SA patent/SG11202005451SA/en unknown
- 2018-12-14 KR KR1020207020466A patent/KR20200101394A/ko not_active Ceased
- 2018-12-14 JP JP2020534609A patent/JP2021507712A/ja active Pending
- 2018-12-14 CN CN202410465677.6A patent/CN118308379A/zh active Pending
- 2018-12-14 EP EP18845444.1A patent/EP3728291A1/en active Pending
- 2018-12-14 WO PCT/IB2018/060101 patent/WO2019123169A1/en not_active Ceased
- 2018-12-14 US US16/770,963 patent/US11773139B2/en active Active
- 2018-12-14 AU AU2018392884A patent/AU2018392884B2/en not_active Ceased
- 2018-12-14 MX MX2020006225A patent/MX2020006225A/es unknown
- 2018-12-14 EA EA202091178A patent/EA202091178A1/ru unknown
- 2018-12-14 CN CN201880089867.5A patent/CN111801342A/zh active Pending
-
2020
- 2020-06-11 IL IL275296A patent/IL275296A/en unknown
-
2023
- 2023-07-25 US US18/358,350 patent/US12264179B2/en active Active
- 2023-08-02 JP JP2023126388A patent/JP7698678B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021507712A5 (enExample) | ||
| JP2017503482A5 (enExample) | ||
| JP2020520662A5 (enExample) | ||
| JP2009523422A5 (enExample) | ||
| JP2002542827A5 (enExample) | ||
| JP2020516264A5 (enExample) | ||
| JP2018537087A5 (enExample) | ||
| JP2019530462A5 (enExample) | ||
| RU2019139064A (ru) | Композиции и способы для лечения цитомегаловируса | |
| JP2015501840A5 (enExample) | ||
| JP2018520997A5 (enExample) | ||
| JP2014527404A5 (enExample) | ||
| JP2017513502A5 (enExample) | ||
| FI3872085T3 (fi) | Esimuotoiset virussekvenssit ja niiden käytöt | |
| JP2007516696A5 (enExample) | ||
| JP2011004753A5 (enExample) | ||
| JP2013523718A5 (enExample) | ||
| HRP20100240T1 (hr) | Polipeptidi za indukciju zaštitnog imunitetnog odgovora protiv staphylococcus aureus | |
| RU2015155821A (ru) | Вакцины против малярии | |
| MX2020002876A (es) | Metodo para la induccion segura de inmunidad contra el vsr. | |
| JP2016513115A5 (enExample) | ||
| JP2008533988A5 (enExample) | ||
| JP2021503962A5 (enExample) | ||
| JP2018537089A5 (enExample) | ||
| JP2019505567A5 (enExample) |